vs
JBG SMITH Properties（JBGS）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是JBG SMITH Properties的1.6倍（$207.3M vs $127.6M），JBG SMITH Properties净利率更高（-35.7% vs -62.0%，领先26.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -2.5%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -6.3%）
JBG SMITH Properties是一家总部位于马里兰州贝塞斯达的上市房地产投资信托公司，专注于持有并运营房地产资产，是美国商业地产领域的专业运营机构，面向市场提供多元化的不动产投资与管理服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
JBGS vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $127.6M | $207.3M |
| 净利润 | $-45.5M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | -47.5% | -54.7% |
| 净利率 | -35.7% | -62.0% |
| 营收同比 | -2.5% | 25.9% |
| 净利润同比 | 24.0% | 3.5% |
| 每股收益（稀释后） | $-0.76 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $127.6M | $207.3M | ||
| Q3 25 | $123.9M | $159.9M | ||
| Q2 25 | $126.5M | $166.5M | ||
| Q1 25 | $120.7M | $139.3M | ||
| Q4 24 | $130.8M | $164.6M | ||
| Q3 24 | $136.0M | $139.5M | ||
| Q2 24 | $135.3M | $147.0M | ||
| Q1 24 | $145.2M | $108.8M |
| Q4 25 | $-45.5M | $-128.6M | ||
| Q3 25 | $-28.6M | $-180.4M | ||
| Q2 25 | $-19.2M | $-115.0M | ||
| Q1 25 | $-45.7M | $-151.1M | ||
| Q4 24 | $-59.9M | $-133.2M | ||
| Q3 24 | $-27.0M | $-133.5M | ||
| Q2 24 | $-24.4M | $-131.6M | ||
| Q1 24 | $-32.3M | $-170.7M |
| Q4 25 | -47.5% | -54.7% | ||
| Q3 25 | -27.5% | -106.9% | ||
| Q2 25 | -18.4% | -64.8% | ||
| Q1 25 | -44.7% | -102.6% | ||
| Q4 24 | -53.6% | -74.3% | ||
| Q3 24 | -22.4% | -94.6% | ||
| Q2 24 | -24.3% | -79.1% | ||
| Q1 24 | -30.1% | -151.9% |
| Q4 25 | -35.7% | -62.0% | ||
| Q3 25 | -23.1% | -112.8% | ||
| Q2 25 | -15.2% | -69.0% | ||
| Q1 25 | -37.9% | -108.5% | ||
| Q4 24 | -45.8% | -80.9% | ||
| Q3 24 | -19.8% | -95.7% | ||
| Q2 24 | -18.0% | -89.5% | ||
| Q1 24 | -22.2% | -156.8% |
| Q4 25 | $-0.76 | $-1.28 | ||
| Q3 25 | $-0.48 | $-1.81 | ||
| Q2 25 | $-0.29 | $-1.17 | ||
| Q1 25 | $-0.56 | $-1.57 | ||
| Q4 24 | $-0.70 | $-1.34 | ||
| Q3 24 | $-0.32 | $-1.40 | ||
| Q2 24 | $-0.27 | $-1.52 | ||
| Q1 24 | $-0.36 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $75.3M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $-80.0M |
| 总资产 | $4.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $75.3M | $421.0M | ||
| Q3 25 | $64.4M | $202.5M | ||
| Q2 25 | $61.4M | $176.3M | ||
| Q1 25 | $81.3M | $127.1M | ||
| Q4 24 | $145.8M | $174.0M | ||
| Q3 24 | $137.0M | $150.6M | ||
| Q2 24 | $163.5M | $480.7M | ||
| Q1 24 | $220.5M | $112.3M |
| Q4 25 | $1.2B | $-80.0M | ||
| Q3 25 | $1.2B | $9.2M | ||
| Q2 25 | $1.3B | $151.3M | ||
| Q1 25 | $1.6B | $144.2M | ||
| Q4 24 | $1.8B | $255.0M | ||
| Q3 24 | $1.9B | $346.8M | ||
| Q2 24 | $2.0B | $432.4M | ||
| Q1 24 | $2.1B | $140.3M |
| Q4 25 | $4.4B | $1.5B | ||
| Q3 25 | $4.4B | $1.2B | ||
| Q2 25 | $4.5B | $1.3B | ||
| Q1 25 | $4.7B | $1.3B | ||
| Q4 24 | $5.0B | $1.5B | ||
| Q3 24 | $5.2B | $1.5B | ||
| Q2 24 | $5.3B | $1.6B | ||
| Q1 24 | $5.4B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $73.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $73.3M | $-99.8M | ||
| Q3 25 | $8.9M | $-91.4M | ||
| Q2 25 | $18.8M | $-108.3M | ||
| Q1 25 | $12.9M | $-166.5M | ||
| Q4 24 | $129.4M | $-79.3M | ||
| Q3 24 | $26.4M | $-67.0M | ||
| Q2 24 | $23.8M | $-77.0M | ||
| Q1 24 | $37.0M | $-190.7M |
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JBGS
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
